It’s become commonplace to see monthly pricing of $10,000 for new cancer drugs, but with competition in mind Boehringer takes a conservative approach with its non-small-cell lung cancer drug Gilotrif (afatinib).
Boehringer Ingelheim GMBH has taken a conservative approach to the U.S. launch of its first cancer drug Gilotrif (afatinib), pricing it at $5,500 a month, just below the $5,800 cost for Roche/Astellas Pharma Inc.’s entrenched, competing lung cancer drug Tarceva (erlotinib).
Boehringer launched Gilotrif in the U.S. the week of Sept
Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.
Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.
Drugmakers are not expecting a big financial hit from tariffs for now, but a report commissioned by the industry trade association PhRMA suggests a potentially steep cost for pharma-sector tariffs.
